ArticleTherapeutic innovation & regulatory science2026
Application of the Child-Pugh Classification in Japanese Drug Labeling: A Cross-Sectional Analysis of Contraindications, Dose Recommendations, and Pharmacokinetic Rationale.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate how the Child-Pugh classification is applied in Japanese prescription drug labeling and to characterize the pharmacokinetic features and evidentiary basis underlying contraindications and dose-related recommendations for hepatic impairment.
methodsWe conducted a cross-sectional review of Japanese prescription drug package inserts available as of October 1, 2025. Drugs explicitly referring to the Child-Pugh classification in Section 2 ("Contraindications") and/or Section 7 ("Precautions for Dosage and Administration") were identified using the Pharmaceuticals and Medical Devices Agency database. Absolute bioavailability, systemic clearance, plasma protein binding, and urinary excretion of unchanged drug were extracted from package inserts and interview forms. Hepatic extraction ratio was approximated and analyzed descriptively.
resultsFifty-one active ingredients were identified, including 35 with Child-Pugh-based contraindications and 29 with dose-related recommendations. Most drugs showed high plasma protein binding, low urinary excretion of unchanged drug, and low hepatic extraction. Median values were 0.62 for bioavailability, 11.5 L/h for clearance, 94.7% for plasma protein binding, 1.0% for urinary excretion of unchanged drug, and 0.12 for hepatic extraction ratio. Pharmacokinetic evidence supporting Child-Pugh class C labeling was available for 23 of 51 drugs overall and 14 of 35 drugs with Child-Pugh-based contraindications.
conclusionsChild-Pugh-based labeling in Japan was broadly consistent with hepatic clearance principles, particularly protein binding, renal contribution, and hepatic extraction. However, limited direct pharmacokinetic evidence in severe hepatic impairment indicates the need for clearer justification of whether future recommendations derive from clinical data, modeling, or precautionary inference.
Indexed as
Identifiers
42436313What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.